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Background: Borderline Personality Disorder (BPD) is a serious psychiatric condition associated with substantial
mortality, burden and public health costs. DBT is the treatment model with the largest number of published
research articles showing effectiveness. However, some patients are not sufficiently engaged in outpatient
treatment while presenting severe parasuicidal behavior, making hospitalization necessary. The Center for
Personality Disorders Jelgersma developed an intensive 12-week inpatient DBT program that (i) rapidly reduces core
borderline symptoms like suicidal behavior, (ii) minimizes the negative effects of an inpatient setting, and (iii)
enhances compliance with outpatient treatment. We evaluate the (cost-) effectiveness of this experimental program.
Methods/design: Seventy patients, aged 18 to 45 years with a primary diagnosis of BPD, showing a chronic pattern of
parasuicidal gestures and/or reporting high degrees of severity of other borderline symptoms, are randomly allocated
to the control and intervention groups. Subjects in the control group receive standard outpatient DBT, provided in one
of three regular mental health settings in GGZ Rivierduinen. Subjects in the intervention group receive 12 weeks of
intensified inpatient DBT plus six months of standard DBT, provided in the Center for Personality Disorders Jelgersma.
The primary outcome is the number of suicide attempts/self-harming acts. Secondary outcomes are severity of other
borderline complaints, quality of life, general psychopathological symptoms and health care utilization and productivity
costs. Data are gathered using a prospective, two (group: intervention and control) by five (time of measurement)
repeated measures factorial design.
Participants will complete three-monthly outcome assessments in the course of therapy: at baseline, and 12, 24, 36 and
52 weeks after the start of the treatment. The period of recruitment started in March 2012 and the study will end in
December 2014.
Discussion: Highly suicidal outpatient patients can pose a dilemma for mental health care professionals. Although
hospitalization seems inevitable under some circumstances, it has proven to be harmful in its own right. This paper
outlines the background and methods of a randomized trial evaluating the possible surplus value of a short-term
inpatient DBT program.
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Borderline Personality Disorder (BPD) is a serious and
prevalent psychiatric condition characterized by affective
instability, impulsivity, and significant deficits in the
capacity to work and maintain meaningful relationships.
Patients with BPD struggle with a profound fear of
abandonment, identity disturbances, and paranoid idea-
tions. They are at risk for suicide and repetitive self-
destructive behaviors. BPD patients show a completed
suicide rate that is 50 times greater than that in the gen-
eral population [1,2]. The short- to medium-term out-
come of BPD is poor. There is some evidence that the
long-term follow-up course is more favorable, with re-
mission rates of about 88% within ten years [3]. How-
ever, ‘remission’ means that diagnostic criteria are not
fulfilled. Affective symptoms reflecting areas of dys-
phoria, such as chronic feelings of emptiness, intense
anger or profound abandonment, largely remain [4].
In the general population, the prevalence of BPD var-
ies from 0.4 to 1.8%, with a pooled rate of 1.1% [5]. The
lifetime prevalence of BPD was found to be 5.9% among
a representative sample of the adult population of the
United States [6,7]. In the Netherlands, the number of
borderline patients is estimated at 100,000 [8]. In clinical
samples, BPD is usually the most common personality
disorder. In outpatient samples, rates of 9.3 to 18% have
been reported, with a pooled rate of 11.9% [5]. Studies of
psychiatric inpatient populations have reported rates of
BPD at about 40% [9].
DBT is the BPD treatment model for BPD with the
largest number of evidence-based published research ar-
ticles on effectiveness (13 Random Controled Trials
(RCT) versus 2 RCTs of next evidence treatment model
off the rank). The American Psychological Association,
Society of Clinical Psychology (APA) has cited DBT as
one of the well-established, empirically supported, treat-
ments for BPD that has strong research support [10].
The UK NICE guidelines recognize that, more than any
other therapy, there is some evidence that DBT is effect-
ive in reducing suicide attempts and self-harm, anger,
aggression and depression in patients with BPD [11].
This is also postulated in the Dutch guidelines [12].
Yet, standard DBT is lengthy and thus expensive. More-
over, some BPD patients are not sufficiently engaged in out-
patient treatment and/or experience periodic exacerbations
of severe self-injurious behavior making hospitalization
necessary. A recent meta-analysis showed that psycho-
therapy for BPD yielded an overall drop-out rate of 25%
[13]. Previous research also demonstrated that BPD pa-
tients are hospitalized and readmitted more than those
with other disorders [14,15]. This is troublesome, since
dropping out of treatment, as well as a pattern of inpatient
treatments, adds to the suicide risk [16,17]. These figures
frequently pose a dilemma for mental health careprofessionals treating highly suicidal patients in an out-
patient setting. Hospitalization seems inevitable under
some circumstances, yet has proven harmful in its own
right. It is concluded that there is an urgent need to de-
velop and test short-term inpatient treatment programs
that (i) rapidly reduce core borderline symptoms like
suicidal behavior, (ii) minimize the negative effects of an
inpatient setting, and (iii) enhance compliance with out-
patient treatment.
Following the publication of the SCEPTRE research
results [18], and a growing number of inpatient DBT
programs [19-22], the concept of inpatient treatment
seems to be gaining interest. There is sufficient evidence
that inpatient DBT leads to symptom reduction and that
treatment gains are maintained after discharge for adult
and adolescent BPD patients [23,24]. However, firm con-
clusions about the efficacy of inpatient DBT cannot be
drawn. The effect of inpatient DBT has not been investi-
gated in RCTs or compared to the effect of outpatient
DBT. Moreover, no data on the cost-effectiveness of in-
patient DBT are available.
The Center of Personality Disorders Jelgersma (GGZ
Rivierduinen Leiden, Netherlands) developed an intensive
12-week inpatient DBT program that (i) rapidly reduces
core borderline symptoms like suicidal behavior, (ii)
minimizes negative effects of an inpatient setting, and
(iii) enhances compliance with outpatient treatment.




This is a prospective randomized controlled trial. It is a
two (group: intervention and control) by five (time: pre-
treatment, 12 weeks, 24 weeks, 36 weeks, 52) repeated
measures factorial design. The overall study design is il-
lustrated in Figure 1.
Participants
Participants will consist of seventy patients, aged 18 to
45 years with a primary diagnosis of Borderline Personality
Disorder, according to the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV), showing a
chronic pattern of parasuicidal gestures and/or reporting
high degrees of severity of other borderline symptoms. It
was decided that Jelgersma Center for Personality
Disorders in Oegstgeest, Regional Psychiatric Center
GGZ Rijnstreek, Regional Psychiatric Center GGZ
Leiden and Regional Psychiatric Center GGZ Midden-
Holland, constituting all participating centers of GGZ
Rivierduinen, would implement a central recruiting and
diagnostic facility in order to recruit patients efficiently and
uniformly. All referrals for initial assessment in this facility









































Figure 1 Study design. Procedures in a study comparing experimental short-term inpatient DBT program and standard outpatient DBT.
van den Bosch et al. Trials 2014, 15:152 Page 3 of 9
http://www.trialsjournal.com/content/15/1/152themselves and of their own free will. No restriction is
made in terms of the referral source. Only hard drug abuse
that requires inpatient detoxification and a forced treatment
framework were refused. We predict that the majority
of referrals will come from the Jelgersma Center for
Personality Disorders, since this center has a nation-
wide reputation.
Inclusion criteria
1) Aged between 18 and 45 years
2) Independently contacted the researcher or coached
do to so
3) Fulfill the DSM-IV-TR criteria for BPD. Presence of
BPD is according to semi-structured interview
SCID-II, administered by a trained professional
(psychologist, supervised by a project leader)
4) Show a severe level of borderline symptomatology
(>24 on the Borderline Severity Index)
5) Parasuicidal behavior in the last month preceding
baseline measurement and/or a profound level of
borderline symptoms (>30 on the Borderline
Severity Index)
6) Sufficient command of the Dutch language
7) Within travelling distance from Leiden
8) Understands and agrees with randomization
procedure
Exclusion criteria
1) IQ < 80
2) Chronic psychotic condition3) Bipolar disorder
4) Hard drug abuse that requires inpatient
detoxification
5) Forced treatment framework
6) Started DBT in the year preceding intake
7) Repeatedly fails to return the screening instrument
or does not attend for a thorough examination
8) Disagrees with outcome of randomization
Study conditions
A) Intensified adapted DBT program plus six months
standard outpatient DBT
Twelve-week inpatient DBT was developed in the
Jelgersma Center for Personality Disorders. This
treatment unit provides accommodation for nine
patients. Patients are admitted five days a week. Staff
is only present in the daytime. During the weekends
the patients stay at home. The therapy [16] consists
of DBT skills training [25], individual psychotherapy
(45 minutes a week during the inpatient and the
outpatient program), crisis consultation if needed,
and weekly meetings of the consultation team for all
trainers and therapists for one hour. Staff also
receives supervision twice-weekly.
Individual psychotherapy takes place on a weekly
basis. The order of the topics of each session is
based on Linehan’s protocol [16], and is pre-
determined: suicidal and self-destructive behavior,
therapy-interfering behavior, quality of life-
interfering behavior and generalization of the skills
taught in the training. Each therapy session starts by
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concerning the problematic behaviors, which are the
primary goal of the treatment, but also behaviors
that influence the primary goals (such as alcohol and
drug use, the urge to self-harm, substance abuse,
dissociation, level of applied skills). Skills’ training
takes place during the inpatient program on a
weekly basis, but discussion of theory and homework
classes are separated in time throughout the week
(in total two and a half hours). The skills taught are
standard DBT skills and combine self-regulation and
change skills, and skills for self-acceptance and
acceptance of others: Core mindfulness skills,
Interpersonal effectiveness skills, Emotion regulation
skills, Crises skills and Radical acceptance. Missed
meetings need to be caught up by watching the video
recordings that are made of all the trainings sessions.
Patients also receive daily mindfulness classes, two
hours of drama therapy, psycho-educational classes
about sexuality, substance abuse and medication,
and the possibility of getting help in applying principles
of validation and behavioral analysis skills. Other
program parts are mainly based on living in a group,
such as house-keeping meetings. In order to facilitate
skills generalization, patients and staff developed
psycho-educational evening sessions (two) in which
information on BPD and DBT is given, followed by a
training program (six sessions) in which patients
together with family and friends can get help in
applying skills. Each session lasts two hours. The
first two sessions are spent on psycho-education
about BPD, DBT and the content of the treatment
program. In the next four sessions, all participants
are asked to commit to practice the skills that are
taught in the program with each other.
During evening and night hours, no staff is present.
The results from the data gathered during the
developmental phase of the program (October 2009
to September 2011), show that this does not lead to
an increase in difficulties in handling relationships.
B) Standard outpatient DBT for 12 months
Patients assigned to standard dialectical behavior
therapy receive 12 months of treatment as specified
in the DBT manual [16] in one of the three
participating regional psychiatric centers of
Rivierduinen. The treatment is according to protocol
and combines weekly individual cognitive-behavioral
psychotherapy sessions with the primary therapist
(45 minutes a week, weekly skills-training groups
lasting two and a half hours per session (135 minutes),
and if needed, consultation and weekly consultation
meetings for trainers and therapists (one hour).
Individual therapy, in both in- and outpatient programs,
focuses primarily on motivational issues, including themotivation to stay alive and to stay in treatment.
Group skills training [25] teaches Core Mindfulness
skills, Interpersonal effectiveness skills, Emotion
regulation skills, Crises skills and Radical acceptance.Selection of the therapists
Extensive attention was given to the selection of the thera-
pists. Therapists and skills trainers per condition need to
meet the highest quality requirements of good training,
experience and supervision. All therapists/trainers are psy-
chologists/psychiatrists, or registered nurses/social workers
(n = 30). All have received at least a three-day introductory
training in DBT principles administered by Dialexis, the
training institute of the Dutch DBT association. Supervi-
sion will be given by the main researcher (LMCB), who is
head of the Dutch DBT association and has received ex-
tensive training from Dr. Linehan in Seattle, USA. The
treatment integrity in DBT is protected by systematic
evaluation of video recorded individual and skill training
sessions, by trained adherence coders.
Objectives
The primary objective is to investigate whether this pro-
gram is more effective in declining the proportion of pa-
tients that show parasuicidal behavior in the first three
months of treatment, compared to standard outpatient
DBT. We expect that after 12 weeks of inpatient DBT
treatment, 20% of the patients will still show suicidal/
self-harming behavior (measured by Life Time Parasuicide
Count and items of the Borderline Personality Disorder
Severity Index) compared to 60% of the patients in standard
outpatient DBT. We expect this difference to be sustained
after 24 weeks, though it may be reduced between 24 and
52 weeks.
The secondary objectives are: (i) to investigate whether
short-term inpatient DBT is more effective in reducing
other general (borderline) symptoms, (ii) to investigate
whether short-term inpatient DBT is more effective in
increasing quality of life, and (iii) to assess the cost-
effectiveness of short-term inpatient DBT compared to
outpatient DBT in terms of costs per reduced sui-
cide attempts/self-destructive acts and cost per Quality
Adjusted Life Year (QALY) from a societal perspective.
We expect (i) a stronger decline in Borderline Personality
Disorder Severity Index- and Brief Symptomatology
Inventory scores and (ii) a stronger increase in quality of
life (SF-36 and EQ-5D)-scores in the first three months of
inpatient DBT as compared to the control group. We an-
ticipate this difference to be sustained after 24 weeks,
though it may reduce between 24 and 52 weeks. We also
expect (iii) the initial higher cost of the intensive interven-
tion will lead to better effects and possibly even lower cost
than the control condition. Cost savings may be generated
in the long run (after one year).
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Screening
Vragenlijst voor Kenmerken van de Persoonlijkheid (VKP)
[26], a paper-and-pencil self-report questionnaire that mea-
sures personality disorders as defined in the DSM-III-R
[27] and the International Classification of Diseases, version
10 (, ) [28], was used as a screening test. Next to a categor-
ical diagnosis (‘negative’, ‘probable’ and ‘positive’), it yields a
dimensional score for each disorder. Reliability and validity
have proven to reasonable [29].
Axis I and axis II disorders
For inclusion, patients had to meet the criteria for border-
line personality disorder, as measured by the Dutch transla-
tion of the Structured Clinical Interview for DSM-IV,
version II (SCID-II) [30,31]. The SCID-II is a clinician-
rated semi-structured clinical interview developed to meas-
ure the ten DSM-IV axis II personality disorders, sup-
plemented by the depressive and the passive-aggressive
personality disorder [32]. This instrument has shown ad-
equate interrater and internal consistency reliability [33].
The web-based Dutch version of the Mini International
Neuropsychiatric Interview (MINI-PLUS) [34,35] was used
to assess exclusion criteria. The MINI-PLUS is a struc-
tured clinician-rated diagnostic interview that is used to
determine the most common DSM-IV [32] and ICD-10
psychiatric disorders [28]. Reliability and validity are con-
sidered good [34,36].
The interviewers who conducted the SCID-II and
MINI-PLUS interviews had a master’s degree in psych-
ology. They received training in how to carry out the in-
terviews and were supervised by an experienced clinical
psychologist. The interviewers had the opportunity to
verify their diagnosis with a psychiatrist.
Outcomes
Frequency of suicide attempts/self-harming acts, as mea-
sured by the Lifetime Parasuicide Count (LPC: [37]. The
LPC is a sixteen-item clinician-rated interview that de-
termines parasuicide markers (date, method, intent, and
medical treatment) of respectively the first, most recent
and most severe parasuicide, and determines the frequency
and subsequent medical treatment of 12 methods of self-
mutilating behaviors (for example, cutting, burning and
pricking). Data on the psychometric properties of this in-
strument were not available.
The Borderline Personality Disorder Severity Index
(BPDSI) [38] is a clinician-rated semi-structured inter-
view assessing the frequency of borderline symptoms in
the previous three-month period. The BPDSI-IV has
shown high interrater reliability, moderate to high in-
ternal consistencies and very good discriminant, concur-
rent and construct validity [38,39]. The BPDSI-IV has
been used in various trials and proved to be sensitive tochange among others. [40,41]. Patients have reported
that during the interview they feel their problems are ac-
knowledged [42].
The SF-36 [43], or Medical Outcomes Study 36-Item
Short Form Health Survey, is a short-form, self-report
health survey with 36 questions. It yields an eight-scale
profile of functional health and well-being: Physical
Functioning, Role-Physical, Bodily Pain, General Health,
Vitality, Social Functioning, Role-Emotional and Mental
Health as well as psychometrically-based physical and
mental health summary measures and a preference-based
health utility index. A higher score indicates a better state
of health [43]. A Dutch version was translated and vali-
dated by Aaronson et al. [44]. Data from the SF-36 were
collected using a computer-based version, SF-6D.
SF-6D. The Sheffield Health Economic Group derived
a preference-based measure of health from the SF-36
[45]. The new preference-based measure, known as the
SF-6D, is derived from 11 items of the SF-36 and is
composed of six dimensions of health with four to six
levels each.
The EQ-5D [46], or EuroQol 5 Dimensions descriptive
system, is a paper-and-pencil self-report questionnaire
that consists of five dimensions (Mobility, Self Care, Usual
Activities, Pain/Discomfort and Anxiety/Depression) with
three levels each (no problems, some problems and
extreme problems), thus defining 243 distinct health
states. Each of these health states can be assigned a par-
ticular utility using a scoring algorithm. The Dutch tariffs
were determined in a time trade-off study. EQ-5D utilities
range from −0.329 to 1. Assessment takes one to two
minutes.
The TiC-P or ‘Trimbos and iMTA Questionnaire on
Costs Associated with Psychiatric Illness’ (TiC-P) [47] is a
validated tool commonly applied in economic evaluations
of treatments in mental health care. The TiC-p is a paper-
and-pencil self-report questionnaire that consists of two
parts. The first part measures direct medical costs. The
second part estimates the productivity costs. It includes a
short form of the Health and Labor questionnaire (HLQ),
consisting of three modules that measure productivity
losses: absence from work, reduced efficiency at work and
difficulties with job performance [48]. The TIC-P is con-
sidered to be a feasible and reliable instrument for col-
lecting data on medical consumption and productivity
losses in patients with mental health problems. The
construct validity of questions related to contacts with
psychotherapist and long-term absence from work is
satisfactory [49].
The BSI, or Brief Symptomatology Inventory (BSI) [50],
is a self-report questionnaire that includes 49 items
grouped into nine scales that encompass nine primary
dimensions of psychopathological symptoms: psychoti-
cism, somatization, depression, hostility, phobic anxiety,
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and nervous tension. Derogatis and Melisaratos [50] pre-
sented appropriate coefficients of internal consistency of
the BSI ranging from 0.71 to 0.85, test-retest reliability co-
efficients ranging from 0.68 to 0.91, and evidence for the a
good construct validity of the BSI. Other studies have re-
ported similar estimates, for example, see references
[51,52]. Data of the BSI were collected using a computer-
based version.
Sample size
We expect that after 12 weeks, 20% of the patients of
the intervention group will still show suicidal and/or
self-harming behavior compared to 60% of the patients
in the control condition. To be able to detect a differ-
ence of 40% after 12 weeks, with a power of 0.80 and an
α = 0.05, a minimum of 23 patients per experimental
condition is required. We will randomize between ap-
proximately 70 patients during the study period to guar-




Treatment allocation is carried out by a computer pro-
gram, developed by the Amsterdam Medical Center. To
increase the likelihood of comparable treatment groups,
a minimization method is preferred. To preserve the
random character of allocation, a biased coin procedure
will be used. In case of imbalance, the allocation prob-
ability is modified from 50/50 to 80/20. Minimization
variables are: level of severity of borderline symptomatol-
ogy (BPDSI score ≥ 40), level of suicidality/self-harming
behavior (LPC score ≥ 14), and age.
Allocation concealment
The sequence was concealed until interventions were
assigned.
Implementation
When patients register in the participating psychiatric
centers, crisis team members or staff members working
at the front office decide whether or not this patient is a
candidate for DBT, based on a rapid assessment of BPD
symptomatology. Patients are informed about the central
recruitment and diagnostic facility and are given the
phone numbers of the project leader and coordinator.
After a short, standardized telephone interview with the
project leader or the coordinator, in which general informa-
tion on the interventions and study is given, patients need
to fill out a screening instrument (Vragenlijst Kenmerken
Persoonlijkheid, VKP) [26] and send it back to the central
diagnostic facility. Subsequently, a psychologist contacts
the patient for a briefing of the results. If the screeninginstrument indicates that presence of BPD is probable,
then psychologist and patient make an appointment for a
thorough examination within three weeks. During this
thorough examination, with use of the MINI-PLUS and
SCID-II, presence of DSM axis I and axis II disorders are
verified. Frequency of borderline complaints and parasui-
cidal gestures are assessed using respectively BPDSI and
LPC. All assessment tools employed have demonstrated
reliability and validity (described in detail below). In-
formed consent is discussed and signed. After signing the
informed consent, patients are randomized and the diag-
nostician reports the allocation of the treatment back to
the patients. The allocated treatment center then contacts
the patient and starts treatment.
Blinding
No blinding took place.
Statistical analysis
All participants who are randomised will be included in
the comparison and analyzed according to their random-
ized allocation (intent-to-treat analysis). Wherever pos-
sible, we will continue to collect follow-up data from
participants after they drop out of treatment, so that the
dataset will be as complete as possible. All analyses will
be carried out using SPSS (Statistical Package for the
Social Sciences) 19 [53]. The effect of the intervention in
terms of proportion of respondents still showing suicidal
and/or self-destructive behavior after 12 weeks, and the
retention of this effect between 24, 36 and 52 weeks, will
be computed with the help of longitudinal logistic re-
gression, with time, experimental condition and their
interaction as independent variables. The effect of the
intervention in terms of reduction in mean BPDSI, LPC,
SF-36, and the BSI ratings over time, will be computed
with the help of a mixed model linear regression analysis
with time, experimental condition and their interaction
as independent variables. Missing values will be taken
into account by using full information maximum likeli-
hood method estimation. Since there may be some het-
erogeneity in the implementation of standard DBT
across the three different regional centers, between-
center heterogeneity will be explored in subgroup
analyses.
Cost-effectiveness analysis
The economic evaluation will be undertaken from a soci-
etal perspective. Hence, all relevant effects and costs due
to resource utilization within healthcare (direct medical
costs) and productivity costs will be included. To examine
the cost-effectiveness of the inpatient program compared
to the outpatient program the EQ-5D, the SF-6D, and the
TiC-P, will be used. We will assess the cost-effectiveness
of short-term inpatient DBT compared to outpatient DBT
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destructive acts and cost per QALY, the so-called cost util-
ity analysis. The cost utility will be evaluated by relating
the difference in direct medical costs per patient receiving
inpatient treatment and outpatient care to the difference
in terms of QALYs, which yields a cost per QALY esti-
mate. We will estimate the cost per QALY including prod-
uctivity costs.
The uncertainty will be assessed using bootstrapping,
and the results will be presented in acceptability curves.
Ethical precautions and crisis management
The study will be executed in accordance with the
guidelines for Good Clinical Practice, the principles
of the Declaration of Helsinki, the Medical Research
Involving Human Subjects Act (WMO) and other guide-
lines, regulations and Acts as currently used in GGZ
Rivierduinen. Ethical approval is obtained from the eth-
ical review board of the Leiden University Medical cen-
ter. The board of Rivierduinen agreed to support the
execution of the study. All the boards of the psychiatric
regional centers that take part in the study also gave
agreement. All participants will be extensively informed
about the study, addressing confidentiality, the right to
abort their participation at any time and without clarifi-
cation. Patients can leave the research program any time
they want, and this will not affect the course of their
treatment. Written information is given. When the pa-
tient is willing to continue, written consent is asked. A
computer program, developed by the Amsterdam Medical
Center, carries out treatment allocation. This program rules
out determination of group assignment, which guaran-
tees impartiality of the researchers. The diagnostics and
follow-up measurements take place in the Jelgersma
Center. An independent physician is appointed, to
whom subjects can address questions about the re-
search before, during and after a study. The indepen-
dent physician does not work at the institution where
the study is being carried out, and is not involved in
the study itself. Patients will receive a voucher of 10
euros for each repeated measurement, and restitution
of their travel expenses.
Discussion
Mental health care professionals are frequently con-
fronted by a dilemma when treating highly suicidal pa-
tients in an outpatient setting. Hospitalization seems
inevitable under some circumstances, yet has proven
harmful in its own right. This paper outlines the back-
ground and methods of a randomized trial evaluating
the possible surplus value of a short-term inpatient DBT
program.
Although previous quasi-experimental studies [22,23]
have shown positive effects of inpatient DBT, the settingcould add to the risk of regressive processes during treat-
ment. Therefore we evaluated outcomes of the experimen-
tal short-term inpatient DBT program of the Jelgersma
Center in a quasi-experimental study, comparing pre- and
post-intervention data for 39 female patients with a diag-
nosis of BPD [54]. It was found that the severity of border-
line problems, particularly in the field of interpersonal
problems, was significantly reduced. In general, suicidality
and parasuicidal behavior were not reduced significantly,
though positive effects for patients reporting high levels of
suicide attempts and self-harming behavior at baseline
were found. It was concluded that the experimental pro-
gram showed promise for patients who show high levels
of parasuicidal behavior and that further development and
research was justified. Improvements were suggested and
implemented [54]. One of the most important changes
made was restricting the program to patients with recent
suicide attempts and severe self-harming behavior.
Four centers of GGZ Rivierduinen (Center of Personality
Disorders Jelgersma, GGZ Rijnstreek, GGZ Leiden en
GGZ Midden-Holland) agreed to participate in the trial.
In order to rule out differences in the admittance process,
an independent, central diagnostic facility was established.
This resulted in an efficient, standardized intake proced-
ure that bypasses the waiting lists in the centers. This
adaption was considered to be beneficial for participants,
since they know their diagnosis and the treatment program
they will be part of within a few weeks.
However, problems can be expected as a result of the
randomization. The fact that allocation of setting is ran-
dom (outpatient versus inpatient) will create an important
toll for participants, because they may be randomized to a
treatment condition that was not their primary choice.
This involves acceptance of uncertainty. Furthermore,
allocation to the experimental program involves an in-
patient setting for 12 weeks, which may be difficult to
organize for patients with families and work.
Another important problem results from the fact that
although an independent, central diagnostic facility was
created, the study has no influence on the speed with
which patients enter the treatment conditions. The out-
patient DBT teams that are part of the trial have a lim-




BPD: Borderline Personality Disorder; BPDSI: Borderline Personality Disorder
Severity Index; BSI: Brief Symptomatology Inventory; DBT: Dialectical Behavior
Therapy; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, version
IV; EQ-5D: EuroQol 5 Dimensions; HLQ: Health and Labor questionnaire;
ICD-10: International Classification of Diseases, version 10; LPC: Lifetime
Parasuicide Count; MINI-PLUS: A web-based Dutch version of the Mini
International Neuropsychiatric Interview; QALY: Quality Adjusted Life Year;
SF-36: Medical Outcomes Study 36-Item Short Form Health Survey;
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http://www.trialsjournal.com/content/15/1/152SF-6D: Six dimensions of health derived from the SF-36; TiC-P: Trimbos
and iMTA Questionnaire on Costs associated with Psychiatric illness.
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